Summary
This 8-K filing by Edwards Lifesciences Corporation on February 26, 2014, primarily announces two key changes. Firstly, the company appointed Robert W.A. Sellers as its Principal Accounting Officer, effective February 20, 2014. Mr. Sellers brings extensive financial experience, having served as Corporate Controller since 2006 and holding various roles previously, including at Baxter International and Price Waterhouse. Secondly, the Board of Directors amended and restated the company's Bylaws on February 20, 2014. Significant changes include empowering stockholders holding 25% of common stock to call special meetings, clarifying procedures for director elections and stockholder proposals, and establishing the Delaware Court of Chancery as the exclusive forum for certain litigation. These amendments aim to refine corporate governance and procedural aspects.
Key Highlights
- 1Robert W.A. Sellers appointed as Principal Accounting Officer, effective February 20, 2014.
- 2Mr. Sellers has a strong financial background, including his tenure as Corporate Controller since 2006.
- 3The company's Bylaws were amended and restated on February 20, 2014.
- 4Stockholders owning 25% of common stock now have the right to call special meetings.
- 5Clarified rules regarding the nomination of directors and submission of new business proposals by stockholders.
- 6Established the Delaware Court of Chancery as the exclusive forum for certain company-related litigation.
- 7Amendments include technical, conforming, and clarifying changes to the Bylaws.